Stock MRK MERCK & CO., INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Merck & Co., Inc.

Equities

MRK

US58933Y1055

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-31 pm EDT 		5-day change 1st Jan Change
125.5 USD +0.81% Intraday chart for Merck & Co., Inc. -3.05% +15.15%
May. 31 Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival RE
May. 31 Sector Update: Health Care MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Anaveon announces IND approval of ANV600-001 Phase I/II clinical study
AQ
FDA Grants Priority Review to Merck's Application for KEYTRUDA plus Chemotherapy as First-Line Treatment of Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
AQ
Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival Endpoint in Patients with High-Risk Early-Stage Triple Negative Breast Cancer
AQ
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
AQ
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
BU
Merck to Acquire EyeBio
BU
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results
AQ
Merck Announces Third-Quarter 2024 Dividend
BU
Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
BU
BioInvent Presents Promising Clinical Efficacy and Safety for anti-TNFR2 agent BI-1808 at ASCO 2024
AQ
BioInvent Presents Promising Phase 1 Data for BI-1206 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors at ASCO 2024
AQ
MSD collaboration to drive development of solid tumour combination therapy
AQ
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation
AQ
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
BU
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer
AQ
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
BU
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA plus Chemotherapy, With or Without Radiotherapy, for Patients with Newly Diagnosed, High-Risk Endometrial Cancer
AQ
Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy
AQ
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
BU
Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRK Stock
  4. News Merck & Co., Inc.
  5. Press Releases